{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:32:50Z","timestamp":1792650770076,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00415-025-13123-y","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T14:14:18Z","timestamp":1747923258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patients\u2019 experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa\/foscarbidopa in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"272","clinical-trial-number":[{"clinical-trial-number":"nct04750226","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-1327","authenticated-orcid":false,"given":"Michael","family":"Soileau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Parab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triza","family":"Brion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailee","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio F.","family":"Facheris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Shewale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Aldred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"1","key":"13123_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-neuro-100720-034518","volume":"44","author":"GE V\u00e1zquez-V\u00e9lez","year":"2021","unstructured":"V\u00e1zquez-V\u00e9lez GE, Zoghbi HY (2021) Parkinson\u2019s disease genetics and pathophysiology. Annu Rev Neurosci 44(1):87\u2013108","journal-title":"Annu Rev Neurosci"},{"issue":"6","key":"13123_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6):548\u2013560","journal-title":"JAMA"},{"issue":"6","key":"13123_CR3","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.4103\/NRR.NRR-D-23-01660","volume":"20","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Qi Z, Zhu H, Shen K, Liu R, Fang C et al (2024) Role of the globus pallidus in motor and non-motor symptoms of Parkinson\u2019s disease. Neural Regen Res 20(6):1628\u20131643","journal-title":"Neural Regen Res"},{"issue":"10","key":"13123_CR4","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000012444","volume":"97","author":"J Prasuhn","year":"2021","unstructured":"Prasuhn J, Prasuhn M, Fellbrich A, Strautz R, Lemmer F, Dreischmeier S et al (2021) Association of locus coeruleus and substantia nigra pathology with cognitive and motor functions in patients with Parkinson disease. Neurology 97(10):e1007\u2013e1016","journal-title":"Neurology"},{"issue":"1","key":"13123_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","volume":"6","author":"W Yang","year":"2020","unstructured":"Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL et al (2020) Current and projected future economic burden of Parkinson\u2019s disease in the U.S. NPJ Park\u2019s Dis 6(1):15","journal-title":"NPJ Park\u2019s Dis"},{"key":"13123_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.683094","volume":"12","author":"E Kurpershoek","year":"2021","unstructured":"Kurpershoek E, Hillen MA, Medendorp NM, de Bie RMA, de Visser M, Dijk JM (2021) Advanced care planning in Parkinson\u2019s disease: in-depth interviews with patients on experiences and needs. Front Neurol 12:683094","journal-title":"Front Neurol"},{"issue":"7","key":"13123_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T (2021) Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol 20(7):559\u2013572","journal-title":"Lancet Neurol"},{"issue":"1","key":"13123_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1212\/CPJ.0000000000000746","volume":"10","author":"CG Tarolli","year":"2020","unstructured":"Tarolli CG, Zimmerman GA, Auinger P, McIntosh S, Horowitz RK, Kluger BM et al (2020) Symptom burden among individuals with Parkinson disease: a national survey. Neurol Clin Pract 10(1):65\u201372","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"13123_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/08919887231195219","volume":"37","author":"WW Aamodt","year":"2024","unstructured":"Aamodt WW, Kluger BM, Mirham M, Job A, Lettenberger SE, Mosley PE et al (2024) Caregiver burden in Parkinson disease: a scoping review of the literature from 2017\u20132022. J Geriatr Psychiatry Neurol 37(2):96\u2013113","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"1","key":"13123_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40801-023-00410-1","volume":"11","author":"KR Chaudhuri","year":"2024","unstructured":"Chaudhuri KR, Azulay JP, Odin P, Lindvall S, Domingos J, Alobaidi A et al (2024) Economic burden of Parkinson\u2019s disease: a multinational, real-world, cost-of-illness study. Drugs Real World Outcomes 11(1):1\u201311","journal-title":"Drugs Real World Outcomes"},{"issue":"10423","key":"13123_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","volume":"403","author":"T Foltynie","year":"2024","unstructured":"Foltynie T, Bruno V, Fox S, K\u00fchn AA, Lindop F, Lees AJ (2024) Medical, surgical, and physical treatments for Parkinson\u2019s disease. Lancet 403(10423):305\u2013324","journal-title":"Lancet"},{"key":"13123_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105495","volume":"114","author":"SH Isaacson","year":"2023","unstructured":"Isaacson SH, Kremens D, Torres-Yaghi Y, Stocchi F, Antonini A (2023) Importance of time to ON versus wearing OFF in total daily OFF time experienced by patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 114:105495","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"13123_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14737175.2023.2176220","volume":"23","author":"A Lees","year":"2023","unstructured":"Lees A, Tolosa E, Stocchi F, Ferreira JJ, Rascol O, Antonini A et al (2023) Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Rev Neurother 23(1):15\u201324","journal-title":"Expert Rev Neurother"},{"key":"13123_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3389\/fneur.2019.00799","volume":"10","author":"I Straka","year":"2019","unstructured":"Straka I, Min\u00e1r M, \u0160korv\u00e1nek M, Grofik M, Danterov\u00e1 K, Benetin J et al (2019) Adherence to pharmacotherapy in patients with Parkinson\u2019s disease taking three and more daily doses of medication. Front Neurol 10:799","journal-title":"Front Neurol"},{"issue":"1","key":"13123_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41531-022-00421-9","volume":"8","author":"B Labeit","year":"2022","unstructured":"Labeit B, Berkovich E, Claus I, Roderigo M, Schwake AL, Izgelov D et al (2022) Dysphagia for medication in Parkinson\u2019s disease. NPJ Park\u2019s Dis 8(1):156","journal-title":"NPJ Park\u2019s Dis"},{"issue":"2","key":"13123_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","volume":"15","author":"D Nyholm","year":"2013","unstructured":"Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S et al (2013) Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease patients. AAPS J 15(2):316\u2013323","journal-title":"AAPS J"},{"key":"13123_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fneur.2020.00370","volume":"11","author":"KJ Black","year":"2020","unstructured":"Black KJ, Acevedo HK, Koller JM (2020) Dopamine buffering capacity imaging: a pharmacodynamic fMRI method for staging Parkinson disease. Front Neurol 11:370","journal-title":"Front Neurol"},{"issue":"1","key":"13123_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12883-021-02074-2","volume":"21","author":"A Thach","year":"2021","unstructured":"Thach A, Jones E, Pappert E, Pike J, Wright J, Gillespie A (2021) Real-world assessment of the impact of \u201cOFF\u201d episodes on health-related quality of life among patients with Parkinson\u2019s disease in the United States. BMC Neurol 21(1):46","journal-title":"BMC Neurol"},{"issue":"2","key":"13123_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40120-022-00435-8","volume":"12","author":"M Fabbri","year":"2023","unstructured":"Fabbri M, Barbosa R, Rascol O (2023) Off-time treatment options for Parkinson\u2019s disease. Neurol Ther 12(2):391\u2013424","journal-title":"Neurol Ther"},{"issue":"6","key":"13123_CR20","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1007\/s10072-021-05833-8","volume":"43","author":"ED Prete","year":"2022","unstructured":"Prete ED, Schmitt E, Meoni S, Fraix V, Castrioto A, Pelissier P et al (2022) Do neuropsychiatric fluctuations temporally match motor fluctuations in Parkinson\u2019s disease? Neurol Sci 43(6):3641\u20133647","journal-title":"Neurol Sci"},{"issue":"6","key":"13123_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/mds.28599","volume":"36","author":"FAP Nijhuis","year":"2021","unstructured":"Nijhuis FAP, Esselink R, de Bie RMA, Groenewoud H, Bloem BR, Post B et al (2021) Translating evidence to advanced Parkinson\u2019s disease patients: a systematic review and meta-analysis. Mov Disord 36(6):1293\u20131307","journal-title":"Mov Disord"},{"issue":"8","key":"13123_CR22","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","volume":"16","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Romoli M, Calabresi P (2018) Levodopa in Parkinson\u2019s disease: current status and future developments. Curr Neuropharmacol 16(8):1239\u20131252","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"13123_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11096-021-01312-4","volume":"44","author":"SA Jacob","year":"2022","unstructured":"Jacob SA, Wong ZJ, Cheong WL, Chong EYC, Wong YX, Lew SLH (2022) A qualitative exploration of the healthcare challenges and pharmaceutical care needs of people with Parkinson\u2019s and their caregivers. Int J Clin Pharm 44(1):53\u201363","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"13123_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/0308022618770142","volume":"81","author":"M Sperens","year":"2018","unstructured":"Sperens M, Hamberg K, Hariz GM (2018) Challenges and strategies among women and men with Parkinson\u2019s disease: striving toward joie de vivre in daily life. Br J Occup Ther 81(12):700\u2013708","journal-title":"Br J Occup Ther"},{"issue":"1","key":"13123_CR25","doi-asserted-by":"publisher","first-page":"2018769","DOI":"10.1080\/17482631.2021.2018769","volume":"17","author":"YW Chen","year":"2022","unstructured":"Chen YW, Huang CY, Chen JH, Hsiao CL, Hong CT, Wu CY et al (2022) Living with Parkinson\u2019s disease: disease and medication experiences of patients and caregivers. Int J Qual Stud Health Well-Being 17(1):2018769","journal-title":"Int J Qual Stud Health Well-Being"},{"issue":"4","key":"13123_CR26","first-page":"1597","volume":"11","author":"QY Tan","year":"2021","unstructured":"Tan QY, Cox NJ, Lim SER, Coutts L, Fraser SDS, Roberts HC et al (2021) The experiences of treatment burden in people with Parkinson\u2019s disease and their caregivers: a systematic review of qualitative studies. J Park\u2019s Dis 11(4):1597\u20131617","journal-title":"J Park\u2019s Dis"},{"key":"13123_CR27","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.2147\/PPA.S473991","volume":"18","author":"K Richards","year":"2024","unstructured":"Richards K, Mantri S, Brown CM, Johnsrud M, Arcona S, Sasan\u00e9 R (2024) A qualitative study on perspectives of Parkinson\u2019s disease medications: insights from patient focus groups. Patient Prefer Adher 18:1919\u20131928","journal-title":"Patient Prefer Adher"},{"issue":"5","key":"13123_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/mdc3.12672","volume":"5","author":"T Rastgardani","year":"2018","unstructured":"Rastgardani T, Armstrong MJ, Gagliardi AR, Marras C (2018) Understanding, impact, and communication of \u201coff\u201d periods in parkinson\u2019s disease: a scoping review. Mov Disord Clin Pract 5(5):461\u2013470","journal-title":"Mov Disord Clin Pract"},{"key":"13123_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.gerinurse.2022.10.010","volume":"48","author":"S Ahn","year":"2022","unstructured":"Ahn S, Springer K, Gibson JS (2022) Social withdrawal in Parkinson\u2019s disease: a scoping review. Geriatr Nurs 48:251\u2013261","journal-title":"Geriatr Nurs"},{"issue":"9","key":"13123_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/00207454.2020.1853723","volume":"132","author":"ST Aydemir","year":"2022","unstructured":"Aydemir ST, Kumcu MK, Ulukan \u00c7, Bakirarar B, Akbostanc\u0131 MC (2022) Patient preference of device-based treatment of Parkinson\u2019s disease. Int J Neurosci 132(9):925\u2013929","journal-title":"Int J Neurosci"},{"issue":"6","key":"13123_CR31","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F et al (2023) Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12(6):1937\u20131958","journal-title":"Neurol Ther"},{"issue":"12","key":"13123_CR32","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21(12):1099\u20131109","journal-title":"Lancet Neurol"},{"issue":"2","key":"13123_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40120-022-00433-w","volume":"12","author":"MJ Soileau","year":"2023","unstructured":"Soileau MJ, Pagan FL, Fasano A, Rodriguez-Cruz R, Yan CH, Gupta NR et al (2023) Comparative effectiveness of carbidopa\/levodopa enteral suspension and deep brain stimulation on pill burden reduction in medicare fee-for-service patients with advanced Parkinson\u2019s disease. Neurol Ther 12(2):459\u2013478","journal-title":"Neurol Ther"},{"issue":"11","key":"13123_CR34","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","volume":"130","author":"M Auffret","year":"2023","unstructured":"Auffret M, Weiss D, Stocchi F, V\u00e9rin M, Jost WH (2023) Access to device-aided therapies in advanced Parkinson\u2019s disease: navigating clinician biases, patient preference, and prognostic uncertainty. J Neural Transm 130(11):1411\u20131432","journal-title":"J Neural Transm"},{"issue":"9","key":"13123_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","volume":"33","author":"F Carbone","year":"2019","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson\u2019s disease: efficacy and safety of current and new formulations. CNS Drugs 33(9):905\u2013918","journal-title":"CNS Drugs"},{"key":"13123_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100239","volume":"10","author":"VSC Fung","year":"2024","unstructured":"Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M et al (2024) Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: considerations for initiation and maintenance. Clin Parkinsonism Relat Disord 10:100239","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"1","key":"13123_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ana.26073","volume":"90","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Voight EA, Moussa EM, Jameel F, Lou X, Zhang GGZ et al (2021) Foslevodopa\/foscarbidopa: a new subcutaneous treatment for Parkinson\u2019s disease. Ann Neurol 90(1):52\u201361","journal-title":"Ann Neurol"},{"issue":"1","key":"13123_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41687-020-00219-4","volume":"4","author":"SC Rivera","year":"2020","unstructured":"Rivera SC, McMullan C, Jones L, Kyte D, Slade A, Calvert M (2020) The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders. J Patient Rep Outcomes 4(1):51","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"13123_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12325-019-00920-x","volume":"36","author":"MG Contesse","year":"2019","unstructured":"Contesse MG, Valentine JE, Wall TE, Leffler MG (2019) The case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: a methodologic overview. Adv Ther 36(5):997\u20131010","journal-title":"Adv Ther"},{"issue":"09","key":"13123_CR40","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2217\/cer-2018-0048","volume":"07","author":"M Bharmal","year":"2018","unstructured":"Bharmal M, Marrel A, Hennessy M, Fofana F, Lambert J, Arnould B (2018) Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights. J Comp Eff Res 07(09):881\u2013890","journal-title":"J Comp Eff Res"},{"key":"13123_CR41","unstructured":"Bergquist F, Aldred J, Carroll C, Danielsen E, Facheris M, Gupta R et al (2024) Long-term safety and efficacy for motor fluctuations and quality of life with foslevodopa\/foscarbidopa in patients with advanced Parkinson\u2019s disease: interim results from an ongoing open label extension [abstract]. Mov Disord [Internet] suppl 1(39). https:\/\/www.mdsabstracts.org\/abstract\/long-term-safety-and-efficacy-for-motor-fluctuations-and-quality-of-life-with-foslevodopa-foscarbidopa-in-patients-with-advanced-parkinsons-disease-interim-results-from-an-ongoing-open-label\/"},{"key":"13123_CR42","unstructured":"Hauser R, Fung V, Kimber T, Klos K, Facheris M, Jeong A, et al. Long-term safety and efficacy of foscarbidopa\/foslevodopa in patients with advanced Parkinson\u2019s disease: results from an ongoing phase 3 open-label extension with up to 1 year follow-up [abstract]. Mov Disord [Internet]. 2024;suppl 1(39). https:\/\/www.mdsabstracts.org\/abstract\/long-term-safety-and-efficacy-of-foscarbidopa-foslevodopa-in-patients-with-advanced-parkinsons-disease-results-from-an-ongoing-phase-3-open-label-extension-with-up-to-1-year-follow-up\/"},{"issue":"1","key":"13123_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12874-018-0594-7","volume":"18","author":"K Vasileiou","year":"2018","unstructured":"Vasileiou K, Barnett J, Thorpe S, Young T (2018) Characterising and justifying sample size sufficiency in interview-based studies: systematic analysis of qualitative health research over a 15-year period. BMC M\u00e9d Res Methodol 18(1):148","journal-title":"BMC M\u00e9d Res Methodol"},{"key":"13123_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN (2022) Sample sizes for saturation in qualitative research: a systematic review of empirical tests. Soc Sci Med 292:114523","journal-title":"Soc Sci Med"},{"key":"13123_CR45","volume-title":"Constructing grounded theory","author":"K Charmaz","year":"2014","unstructured":"Charmaz K (2014) Constructing grounded theory, 2nd edn. SAGE Publications Ltd, New York","edition":"2"},{"key":"13123_CR46","doi-asserted-by":"crossref","unstructured":"Charmaz K, R H, Smith J (1995) Grounded theory. In: Rethinking methods in psychology. Sage Publications, London, pp 27\u201349","DOI":"10.4135\/9781446221792.n3"},{"key":"13123_CR47","doi-asserted-by":"crossref","unstructured":"Glaser BG, Strauss AL (1967) The discovery of grounded theory. In: The discovery of grounded theory: strategies for qualitative research. Aldine de Gruyter, New York, pp 1\u201318","DOI":"10.4324\/9780203793206-1"},{"key":"13123_CR48","doi-asserted-by":"publisher","first-page":"205031211882292","DOI":"10.1177\/2050312118822927","volume":"7","author":"YC Tie","year":"2019","unstructured":"Tie YC, Birks M, Francis K (2019) Grounded theory research: a design framework for novice researchers. SAGE Open Med 7:2050312118822927","journal-title":"SAGE Open Med"},{"issue":"8","key":"13123_CR49","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11136-010-9677-6","volume":"19","author":"KE Lasch","year":"2010","unstructured":"Lasch KE, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M et al (2010) PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res 19(8):1087\u20131096","journal-title":"Qual Life Res"},{"issue":"1","key":"13123_CR50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s43441-020-00203-6","volume":"55","author":"L Lackey","year":"2021","unstructured":"Lackey L, Thompson G, Eggers S (2021) FDA\u2019s benefit\u2013risk framework for human drugs and biologics: role in benefit\u2013risk assessment and analysis of use for drug approvals. Ther Innov Regul Sci 55(1):170\u2013179","journal-title":"Ther Innov Regul Sci"},{"issue":"9","key":"13123_CR51","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1080\/03007995.2021.1953971","volume":"37","author":"SS Jick","year":"2021","unstructured":"Jick SS, Oleske DM, Persson R, Zamudio J, Facheris MF (2021) Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions. Curr M\u00e9d Res Opin 37(9):1563\u20131571","journal-title":"Curr M\u00e9d Res Opin"},{"key":"13123_CR52","unstructured":"VYALEV. VYALEVTM complete: starting with support [Internet]. https:\/\/www.vyalev.com\/vyalev-complete\/starting-with-support"},{"issue":"4","key":"13123_CR53","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s13311-020-00938-y","volume":"17","author":"JRP Zuzu\u00e1rregui","year":"2020","unstructured":"Zuzu\u00e1rregui JRP, During EH (2020) Sleep issues in Parkinson\u2019s disease and their management. Neurotherapeutics 17(4):1480\u20131494","journal-title":"Neurotherapeutics"},{"issue":"7","key":"13123_CR54","first-page":"2029","volume":"12","author":"L Sch\u00fctz","year":"2022","unstructured":"Sch\u00fctz L, Sixel-D\u00f6ring F, Hermann W (2022) Management of sleep disturbances in Parkinson\u2019s disease. J Park\u2019s Dis 12(7):2029\u20132058","journal-title":"J Park\u2019s Dis"},{"issue":"4","key":"13123_CR55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jsps.2018.02.010","volume":"26","author":"ZK Alsairafi","year":"2018","unstructured":"Alsairafi ZK, Smith FJ, Taylor KMG, Alsaleh F, Alattar AT (2018) A qualitative study exploring patients\u2019 experiences regarding insulin pump use. Saudi Pharm J 26(4):487\u2013495","journal-title":"Saudi Pharm J"},{"key":"13123_CR56","doi-asserted-by":"crossref","unstructured":"Ruiz-White I, Kramer L, Philips L, Wong B, Lonergan K, Moreno F (2023) Racial and ethnic disparities in physical and mental health care and clinical trials. J Clin Psychiatry 84(4)","DOI":"10.4088\/JCP.23ah14887"},{"issue":"8","key":"13123_CR57","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E et al (2011) Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: part 2\u2014assessing respondent understanding. Value Health 14(8):978\u2013988","journal-title":"Value Health"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13123-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13123-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13123-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T14:02:43Z","timestamp":1749909763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13123-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13123"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13123-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AbbVie participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. No honoraria or payments were made for authorship. AP, CHY, MBS, PK, and AS are employees of AbbVie (and MS is a former employee of AbbVie) and may hold stock. TB is an employee of ICON Plc and, at the time of the analysis, KW was an employee of Lumanity: both of which received research funds from AbbVie to conduct this study. JA has received research funding from Biogen, Teva, Abbvie, Roche, Lundbeck, Parkinson\u2019s Foundation, Boston Scientific, Bial, UCB, Neurocrine, PhotoPharmics\/Univ Rochester, Annovis, Sage, Aptinyx, Quadralynx, Takeda, Praxis; consulting fees from Supernus, Abbvie, Boston Scientific; and previously received honoraria from Abbvie, Teva, Neurocrine. MS has received advisory\/consulting fees from AbbVie, Abbott, Amneal Pharmaceuticals, Merz therapeutics, Medtronic, Neurocrine, Supernus; research support from AbbVie, Cerevel therapeutics, Cerevance, CND Lifesciences, Intra-cellular Therapies, Jazz Pharmaceuticals, Praxis Precision Medicine, Scion, and Teva; served on the speaking bureau for AbbVie, Amneal pharmaceuticals, Biogen, and Kyowa Kiran; and received grant support from the HDSA. RK: has received consulting fees or honoraria from AbbVie, Annexon, Cerevel Therapeutics, Roche\/Genentech, Supernus Pharmaceuticals, and Teva Pharmaceuticals; is a member of the speakers'bureau for Kyowa Kirin and Teva Pharmaceuticals; has stock ownership in CenExel Clinical Research Holdings and Research Catalyst, LLC; and has received research grant support from AbbVie, Alexa Pharmaceuticals, Annexon Biosciences, Annovis, Bial, Biogen, Biohaven, Biovie, Cerevance, Cerevel Therapeutics, CHDI Foundation, CND Life Sciences, Cognition Therapeutics, Eli Lilly, Ferrer, Lundbeck, Neurocrine Biosciences, Neuroderm, Ono pharmaceuticals, Prilenia Therapeutics, PTC Therapeutics, Roche, Sage Therapeutics, Scion Neurostim, Supernus Pharmaceuticals, Teva Pharmaceuticals, Transposon Therapeutics, UCB, Uniqure Biopharma, and Vigil Neuroscience.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Full ethics review and approval were obtained from the institutional review board and were performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. All participants gave their informed consent prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}],"article-number":"416"}}